BRIEF-Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer

Reuters

10 Apr

BRIEF-Pasithea <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer

April 10 (Reuters) - Pasithea Therapeutics Corp KTTA.O:

PASITHEA THERAPEUTICS ANNOUNCES POSITIVE SAFETY REVIEW COMMITTEE $(SRC)$ RECOMMENDATION FROM ITS ONGOING PHASE 1 CLINICAL TRIAL OF PAS-004 IN ADVANCED CANCER
PASITHEA THERAPEUTICS CORP - NO DOSE-LIMITING TOXICITIES (DLT'S) OR RASH OBSERVED TO DATE
PASITHEA THERAPEUTICS CORP - SRC RECOMMENDED THAT TRIAL ESCALATE TO NEXT DOSE LEVEL OF 30MG CAPSULE

Source text: ID:nGNX9HpRyQ

Further company coverage: KTTA.O

(((( Reuters.briefs@thomsonreuters.com ;));))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2526554735"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2526554735\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2526554735?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-10 19:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2526554735","market":"us","top_or_hot":-1,"title":"BRIEF-Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pasithea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer</title></head><body><p><span>April 10 (Reuters)</span><span> - </span>Pasithea Therapeutics Corp <span>KTTA.O</span>:</p><ul><li><p>PASITHEA THERAPEUTICS ANNOUNCES POSITIVE SAFETY REVIEW COMMITTEE <a href=\"https://laohu8.com/S/SRC\">$(SRC)$</a> RECOMMENDATION FROM ITS ONGOING PHASE 1 CLINICAL TRIAL OF PAS-004 IN ADVANCED CANCER</p></li><li><p>PASITHEA THERAPEUTICS CORP - NO DOSE-LIMITING TOXICITIES (DLT'S) OR RASH OBSERVED TO DATE</p></li><li><p>PASITHEA THERAPEUTICS CORP - SRC RECOMMENDED THAT TRIAL ESCALATE TO NEXT DOSE LEVEL OF 30MG CAPSULE</p></li></ul><p>Source text: <span>ID:nGNX9HpRyQ</span></p><p>Further company coverage: <span>KTTA.O</span></p><p> (((( Reuters.briefs@thomsonreuters.com ;));))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-10 19:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Pasithea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer</title></head><body><p><span>April 10 (Reuters)</span><span> - </span>Pasithea Therapeutics Corp <span>KTTA.O</span>:</p><ul><li><p>PASITHEA THERAPEUTICS ANNOUNCES POSITIVE SAFETY REVIEW COMMITTEE <a href=\"https://laohu8.com/S/SRC\">$(SRC)$</a> RECOMMENDATION FROM ITS ONGOING PHASE 1 CLINICAL TRIAL OF PAS-004 IN ADVANCED CANCER</p></li><li><p>PASITHEA THERAPEUTICS CORP - NO DOSE-LIMITING TOXICITIES (DLT'S) OR RASH OBSERVED TO DATE</p></li><li><p>PASITHEA THERAPEUTICS CORP - SRC RECOMMENDED THAT TRIAL ESCALATE TO NEXT DOSE LEVEL OF 30MG CAPSULE</p></li></ul><p>Source text: <span>ID:nGNX9HpRyQ</span></p><p>Further company coverage: <span>KTTA.O</span></p><p> (((( Reuters.briefs@thomsonreuters.com ;));))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nFWN3QN25E:1","article_id":"2526554735","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2526554735","pubTimestamp":1744283522,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced CancerApril 10 (Reuters) - Pasithea Therapeut","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","KTTA":"Pasithea Therapeutics Corp."},"translate_title":"简介-Pasithea Therapeutics宣布安全审查委员会(Src)对其正在进行的Pas-004晚期癌症1期临床试验提出了积极的建议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KTTA":0.9},"content_text":"BRIEF-Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced CancerApril 10 (Reuters) - Pasithea Therapeutics Corp KTTA.O:PASITHEA THERAPEUTICS ANNOUNCES POSITIVE SAFETY REVIEW COMMITTEE $(SRC)$ RECOMMENDATION FROM ITS ONGOING PHASE 1 CLINICAL TRIAL OF PAS-004 IN ADVANCED CANCERPASITHEA THERAPEUTICS CORP - NO DOSE-LIMITING TOXICITIES (DLT'S) OR RASH OBSERVED TO DATEPASITHEA THERAPEUTICS CORP - SRC RECOMMENDED THAT TRIAL ESCALATE TO NEXT DOSE LEVEL OF 30MG CAPSULESource text: ID:nGNX9HpRyQFurther company coverage: KTTA.O (((( Reuters.briefs@thomsonreuters.com ;));))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}